Sasaki A, Sato S, Shinkawa O, Go M, Otsuka T, Sugawara A, Shimizu Y, Murakami O, Hanew K, Andoh N
Department of Internal Medicine, Wakayanagi Hospital.
J Clin Endocrinol Metab. 1988 Jun;66(6):1202-7. doi: 10.1210/jcem-66-6-1202.
Peptide histidine isoleucine (PHI) was initially isolated from the porcine gastrointestinal tract and may be present in the brain. It has been suggested that PHI may be PRL-releasing hormone (PRH) because of its potent PRL-releasing activity and its existence in hypophysial portal plasma in rats. Vasoactive intestinal peptide and PHI are coded by the same gene, and human PHI has a C-terminal methionine instead of isoleucine [peptide histidine methionine (PHM)]. To investigate the possibility that PHM is a physiological PRH in humans, we measured the immunoreactive PHM concentration in human hypothalamic tissue and cerebrospinal fluid (CSF) using a specific RIA. We also examined in vivo the PRH activity of synthetic PHM. The human hypothalamus contained 19.3 +/- 6.2 (+/- SD; n = 5) pmol/hypothalamus, very similar to the content of GHRH or CRH. Immunoreactive PHM was also present in CSF; its levels in CSF were significantly lower in patients with prolactinomas than in control subjects. The CSF PHM levels in such patients increased after correction of hyperprolactinemia by long term bromocriptine therapy. The CSF PHM levels also were low in pregnant women. There was a significant negative correlation between plasma PRL and CSF PHM levels in all of these subjects. Gel filtration profiles of CSF extracts from normal subjects revealed two peaks of immunoreactive PHM: a high mol wt peak and one at the elution position of synthetic PHM. This profile resembled that of hyppothalamic extract. In contrast, only high mol wt material was detected in CSF from hyperprolactinemic subjects. Intravenous administration of synthetic PHM elicited a significant increase in plasma PRL in normal subjects; the responses to PHM were higher in women than in men. The presence of large amounts of immunoreactive PHM in the human hypothalamus suggests that PHM may participate in the regulation of anterior pituitary hormone secretion. Its specific PRL-releasing activity in vivo and the low CSF PHM levels of hyperprolactinemic subjects suggest that PHM may be a physiological PRH in humans.
肽组氨酸异亮氨酸(PHI)最初是从猪胃肠道中分离出来的,可能存在于大脑中。由于其强大的促催乳素释放活性以及在大鼠垂体门脉血浆中的存在,有人提出PHI可能是催乳素释放激素(PRH)。血管活性肠肽和PHI由同一基因编码,人类PHI的C末端是甲硫氨酸而非异亮氨酸[肽组氨酸甲硫氨酸(PHM)]。为了研究PHM是否是人类生理性PRH的可能性,我们使用特异性放射免疫分析法(RIA)测量了人下丘脑组织和脑脊液(CSF)中免疫反应性PHM的浓度。我们还在体内检测了合成PHM的PRH活性。人下丘脑含有19.3±6.2(±标准差;n = 5)pmol/下丘脑,与生长激素释放激素(GHRH)或促肾上腺皮质激素释放激素(CRH)的含量非常相似。CSF中也存在免疫反应性PHM;催乳素瘤患者CSF中的PHM水平显著低于对照组。长期使用溴隐亭治疗纠正高催乳素血症后,此类患者的CSF中PHM水平升高。孕妇的CSF中PHM水平也较低。在所有这些受试者中,血浆催乳素与CSF中PHM水平之间存在显著的负相关。正常受试者CSF提取物的凝胶过滤图谱显示出两个免疫反应性PHM峰:一个高分子量峰和一个位于合成PHM洗脱位置的峰。该图谱类似于下丘脑提取物的图谱。相比之下,高催乳素血症受试者的CSF中仅检测到高分子量物质。静脉注射合成PHM可使正常受试者的血浆催乳素显著升高;女性对PHM的反应高于男性。人下丘脑中大量免疫反应性PHM的存在表明PHM可能参与垂体前叶激素分泌的调节。其在体内的特异性促催乳素释放活性以及高催乳素血症受试者CSF中PHM水平较低表明PHM可能是人类生理性PRH。